HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $4.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintains a $4.5 price target.

March 05, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Unicycive Therapeutics with a $4.5 price target.
The reiteration of a Buy rating and maintenance of a $4.5 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence among investors and potentially lead to a positive short-term impact on UNCY's stock price. Analyst ratings, especially from well-regarded firms, often influence investor sentiment and can lead to price movements.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100